Repare Therapeutics Inc. held its 2025 Annual Meeting of Shareholders on June 17, 2025. During the meeting, shareholders voted on several proposals. David Bonita, M.D., Thomas Civik, Carol A. Schafer, and Steven Stein, M.D. were elected as Class II directors of the Board. Additionally, the shareholders approved the appointment of Ernst & Young LLP as the independent registered public accounting firm for the year ending December 31, 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.